Zobrazeno 1 - 10
of 12
pro vyhledávání: '"William J. Edenfield"'
Autor:
Avery T. Funkhouser, Alexander M. Strigenz, Bailey B. Blair, Andrew P. Miller, Jonah C. Shealy, Joseph A. Ewing, Julie C. Martin, Christopher R. Funk, William J. Edenfield, Anna V. Blenda
Publikováno v:
Cancers, Vol 14, Iss 11, p 2781 (2022)
To investigate a potential role for galectins as biomarkers that enable diagnosis or prognostication of breast or non-small cell lung cancer, the serum levels of galectins -1, -3, -7, -8, and -9 of cancer patients determined by ELISA assays were comp
Externí odkaz:
https://doaj.org/article/c719ea3d6c534a93b9b8d6c5f3f68504
Metastatic ghost cell odontogenic carcinoma: description of a case and search for actionable targets
Publikováno v:
Rare Tumors, Vol 7, Iss 3 (2015)
Ghost cell odontogenic carcinoma (GCOC) is an exceedingly rare malignant tumor on the spectrum of already uncommon odontogenic or dentinogenic tumors. We describe here the case of metastatic GCOC in a patient with a history of recurrent dentinogenic
Externí odkaz:
https://doaj.org/article/1b5a0199b6fb4454bdabe869dad3e735
Autor:
Meena Okera, Brian A. Van Tine, Joleen M. Hubbard, Minal Barve, Erika Hamilton, Monica M. Mita, Frances Valdes-Albini, Daniel Ahn, Admasu Mamuye, Joshua Pelham, Amy Yuet, Diana Yurewicz, Yanning Liu, Andres Machado Sandri, William J. Edenfield, Aki Morikawa, William Gradishar, Rajiv Kumar, Zev A. Wainberg
Publikováno v:
Cancer Research. 83:OT2-11
MT-5111 is a 55kD engineered toxin body targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 works by internalizing, self
Autor:
Alex Kesic, Avery Funkhouser, Jonah Shealy, Julie Martin, W. Larry Gluck, William J. Edenfield, Anna Blenda
Publikováno v:
Cancer Research. 83:P2-26
Glycobiology has proved to be a new frontier in oncology research in recent years. One sector of glycobiology involves examining glycan expression of cancerous cells. Glycans are complex carbohydrates found on cell surfaces, and patterns of aberrant
Autor:
Mary-Ellen Taplin, Karen J. Ferrante, Khalid Mamlouk, William J. Edenfield, Luke T. Nordquist, Alan J. Koletsky, Nicholas J. Vogelzang, Joseph J. Stephenson, Roberto Pili, Franklin Chu, Matthew B. Rettig, Mario A. Eisenberger, Bruce Montgomery
Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0131dafb3a9e6630df68c872cbf7d6fa
https://doi.org/10.1158/1078-0432.22458224
https://doi.org/10.1158/1078-0432.22458224
Autor:
Mary-Ellen Taplin, Karen J. Ferrante, Khalid Mamlouk, William J. Edenfield, Luke T. Nordquist, Alan J. Koletsky, Nicholas J. Vogelzang, Joseph J. Stephenson, Roberto Pili, Franklin Chu, Matthew B. Rettig, Mario A. Eisenberger, Bruce Montgomery
Purpose: Galeterone is a selective, multitargeted agent that inhibits CYP17, antagonizes the androgen receptor (AR), and reduces AR expression in prostate cancer cells by causing an increase in AR protein degradation. These open-label phase I and II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f3751f5bff82843638e91d05f304de
https://doi.org/10.1158/1078-0432.c.6523877.v1
https://doi.org/10.1158/1078-0432.c.6523877.v1
Publikováno v:
Biophysical Journal. 122:330a
Autor:
Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, James R. Berenson, William J. Edenfield, Sanjay Mohan, Gongfu Zhou, Ekaterine Asatiani, Nithya Srinivas, Michael R. Savona
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(7)
The Janus kinase (JAK)/signal transducers and activators of transcription pathway has been implicated in the pathogenesis and progression of various hematologic malignancies. JAK1-regulated cytokines stimulate proliferation and growth of malignant ce
Autor:
Jeffrey R, Infante, Tony R, Reid, Allen L, Cohn, William J, Edenfield, Terrence P, Cescon, John T, Hamm, Imtiaz A, Malik, Thomas A, Rado, Philip J, McGee, Donald A, Richards, Jamal, Tarazi, Brad, Rosbrook, Sinil, Kim, Thomas H, Cartwright
Publikováno v:
Cancer. 119(14)
In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorecta
Autor:
Patricia LoRusso, Drew Rasco, Johanna Bendell, Jasgit Sachdev, Ramesh Ramanathan, Glenn Weiss, Pamela Munster, William J. Edenfield, Kejian Liu, Anne Blackwood-Chirchir, Jorge DiMartino, Daniel D. Von Hoff
Publikováno v:
Molecular Cancer Therapeutics. 12:A120-A120
Background: CC-486, an oral formulation of 5-azacitidine, induces global genomic hypomethylation and clinical responses in MDS patients at doses of 200 mg and 300 mg/day for 14 or 21/28 days with acceptable safety. This non-randomized, multi-center P